Pharmaceutical and biotechnology companies in the US have 234 medicines in the development pipeline for the treatment of childhood diseases, according to a new report.
According to the Pharmaceutical Research and Manufacturers of America (PhRMA) report, pharmaceutical companies and biotechnology companies in particular are making steady progress against childhood diseases.
PhRMA senior vice president Ken Johnson said that infant mortality in America has sunk to record lows.
“25 medicines are being developed for childhood cancer and 36 drugs are being clinically tested to treat genetic disorders,” Johnson said.
The new “Medicines in Development for Children” survey lists 23 new treatments being tested for neurologic disorders, including epilepsy, which afflicts more than 300,000 Americans under the age of 14.
Also listed in the survey are 15 treatments in testing for respiratory disorders, including asthma, which afflicts about 6.7 million American children, and
13 for cardiovascular diseases such as hypertension, high cholesterol and congenital heart disease.
The medicines listed in the report include treatments being developed by Abbott Laboratories, Hospira, Neopharm, Takeda Pharmaceuticals, Astellas Pharma and Lundbeck.